Sacral neuromodulation in the golden years: Treatment outcomes in elderly 75 years and older
CONCLUSIONS: SNM is a safe and effective option in well-selected patients over the age of 75 years. Treatment success rate is comparable to younger cohorts. Advanced age should not preclude third-line therapy options in this population.PMID:37931277 | DOI:10.5489/cuaj.8421 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - November 6, 2023 Category: Urology & Nephrology Authors: Roseanne Ferreira Samuel Otis-Chapados Emad Alwashmi Naeem Bhojani Kevin C Zorn Bilal Chughtai Dean S Elterman Source Type: research
Sacral neuromodulation in the golden years: Treatment outcomes in elderly 75 years and older
CONCLUSIONS: SNM is a safe and effective option in well-selected patients over the age of 75 years. Treatment success rate is comparable to younger cohorts. Advanced age should not preclude third-line therapy options in this population.PMID:37931277 | DOI:10.5489/cuaj.8421 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - November 6, 2023 Category: Urology & Nephrology Authors: Roseanne Ferreira Samuel Otis-Chapados Emad Alwashmi Naeem Bhojani Kevin C Zorn Bilal Chughtai Dean S Elterman Source Type: research
Sacral neuromodulation in the golden years: Treatment outcomes in elderly 75 years and older
CONCLUSIONS: SNM is a safe and effective option in well-selected patients over the age of 75 years. Treatment success rate is comparable to younger cohorts. Advanced age should not preclude third-line therapy options in this population.PMID:37931277 | DOI:10.5489/cuaj.8421 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - November 6, 2023 Category: Urology & Nephrology Authors: Roseanne Ferreira Samuel Otis-Chapados Emad Alwashmi Naeem Bhojani Kevin C Zorn Bilal Chughtai Dean S Elterman Source Type: research
Sacral neuromodulation in the golden years: Treatment outcomes in elderly 75 years and older
CONCLUSIONS: SNM is a safe and effective option in well-selected patients over the age of 75 years. Treatment success rate is comparable to younger cohorts. Advanced age should not preclude third-line therapy options in this population.PMID:37931277 | DOI:10.5489/cuaj.8421 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - November 6, 2023 Category: Urology & Nephrology Authors: Roseanne Ferreira Samuel Otis-Chapados Emad Alwashmi Naeem Bhojani Kevin C Zorn Bilal Chughtai Dean S Elterman Source Type: research
Sacral neuromodulation in the golden years: Treatment outcomes in elderly 75 years and older
CONCLUSIONS: SNM is a safe and effective option in well-selected patients over the age of 75 years. Treatment success rate is comparable to younger cohorts. Advanced age should not preclude third-line therapy options in this population.PMID:37931277 | DOI:10.5489/cuaj.8421 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - November 6, 2023 Category: Urology & Nephrology Authors: Roseanne Ferreira Samuel Otis-Chapados Emad Alwashmi Naeem Bhojani Kevin C Zorn Bilal Chughtai Dean S Elterman Source Type: research
Sacral neuromodulation in the golden years: Treatment outcomes in elderly 75 years and older
CONCLUSIONS: SNM is a safe and effective option in well-selected patients over the age of 75 years. Treatment success rate is comparable to younger cohorts. Advanced age should not preclude third-line therapy options in this population.PMID:37931277 | DOI:10.5489/cuaj.8421 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - November 6, 2023 Category: Urology & Nephrology Authors: Roseanne Ferreira Samuel Otis-Chapados Emad Alwashmi Naeem Bhojani Kevin C Zorn Bilal Chughtai Dean S Elterman Source Type: research
Sacral neuromodulation in the golden years: Treatment outcomes in elderly 75 years and older
CONCLUSIONS: SNM is a safe and effective option in well-selected patients over the age of 75 years. Treatment success rate is comparable to younger cohorts. Advanced age should not preclude third-line therapy options in this population.PMID:37931277 | DOI:10.5489/cuaj.8421 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - November 6, 2023 Category: Urology & Nephrology Authors: Roseanne Ferreira Samuel Otis-Chapados Emad Alwashmi Naeem Bhojani Kevin C Zorn Bilal Chughtai Dean S Elterman Source Type: research
Sacral neuromodulation in the golden years: Treatment outcomes in elderly 75 years and older
CONCLUSIONS: SNM is a safe and effective option in well-selected patients over the age of 75 years. Treatment success rate is comparable to younger cohorts. Advanced age should not preclude third-line therapy options in this population.PMID:37931277 | DOI:10.5489/cuaj.8421 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - November 6, 2023 Category: Urology & Nephrology Authors: Roseanne Ferreira Samuel Otis-Chapados Emad Alwashmi Naeem Bhojani Kevin C Zorn Bilal Chughtai Dean S Elterman Source Type: research
Sacral neuromodulation in the golden years: Treatment outcomes in elderly 75 years and older
CONCLUSIONS: SNM is a safe and effective option in well-selected patients over the age of 75 years. Treatment success rate is comparable to younger cohorts. Advanced age should not preclude third-line therapy options in this population.PMID:37931277 | DOI:10.5489/cuaj.8421 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - November 6, 2023 Category: Urology & Nephrology Authors: Roseanne Ferreira Samuel Otis-Chapados Emad Alwashmi Naeem Bhojani Kevin C Zorn Bilal Chughtai Dean S Elterman Source Type: research
Sacral neuromodulation in the golden years: Treatment outcomes in elderly 75 years and older
CONCLUSIONS: SNM is a safe and effective option in well-selected patients over the age of 75 years. Treatment success rate is comparable to younger cohorts. Advanced age should not preclude third-line therapy options in this population.PMID:37931277 | DOI:10.5489/cuaj.8421 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - November 6, 2023 Category: Urology & Nephrology Authors: Roseanne Ferreira Samuel Otis-Chapados Emad Alwashmi Naeem Bhojani Kevin C Zorn Bilal Chughtai Dean S Elterman Source Type: research
Sacral neuromodulation in the golden years: Treatment outcomes in elderly 75 years and older
CONCLUSIONS: SNM is a safe and effective option in well-selected patients over the age of 75 years. Treatment success rate is comparable to younger cohorts. Advanced age should not preclude third-line therapy options in this population.PMID:37931277 | DOI:10.5489/cuaj.8421 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - November 6, 2023 Category: Urology & Nephrology Authors: Roseanne Ferreira Samuel Otis-Chapados Emad Alwashmi Naeem Bhojani Kevin C Zorn Bilal Chughtai Dean S Elterman Source Type: research
Sacral neuromodulation in the golden years: Treatment outcomes in elderly 75 years and older
CONCLUSIONS: SNM is a safe and effective option in well-selected patients over the age of 75 years. Treatment success rate is comparable to younger cohorts. Advanced age should not preclude third-line therapy options in this population.PMID:37931277 | DOI:10.5489/cuaj.8421 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - November 6, 2023 Category: Urology & Nephrology Authors: Roseanne Ferreira Samuel Otis-Chapados Emad Alwashmi Naeem Bhojani Kevin C Zorn Bilal Chughtai Dean S Elterman Source Type: research
Sacral neuromodulation in the golden years: Treatment outcomes in elderly 75 years and older
CONCLUSIONS: SNM is a safe and effective option in well-selected patients over the age of 75 years. Treatment success rate is comparable to younger cohorts. Advanced age should not preclude third-line therapy options in this population.PMID:37931277 | DOI:10.5489/cuaj.8421 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - November 6, 2023 Category: Urology & Nephrology Authors: Roseanne Ferreira Samuel Otis-Chapados Emad Alwashmi Naeem Bhojani Kevin C Zorn Bilal Chughtai Dean S Elterman Source Type: research
Sacral neuromodulation in the golden years: Treatment outcomes in elderly 75 years and older
CONCLUSIONS: SNM is a safe and effective option in well-selected patients over the age of 75 years. Treatment success rate is comparable to younger cohorts. Advanced age should not preclude third-line therapy options in this population.PMID:37931277 | DOI:10.5489/cuaj.8421 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - November 6, 2023 Category: Urology & Nephrology Authors: Roseanne Ferreira Samuel Otis-Chapados Emad Alwashmi Naeem Bhojani Kevin C Zorn Bilal Chughtai Dean S Elterman Source Type: research
< em > Gardnerella pickettii < /em > sp. nov. (formerly < em > Gardnerella < /em > genomic species 3) and < em > Gardnerella greenwoodii < /em > sp. nov. (formerly < em > Gardnerella < /em > genomic species 8) isolated from female urinary microbiome
Int J Syst Evol Microbiol. 2023 Nov;73(11). doi: 10.1099/ijsem.0.006140.ABSTRACTDuring an ongoing female urinary microbiome research study, strains c17Ua_112T and c31Ua_26T isolated from urine samples of a patient diagnosed with overactive bladder and a healthy postmenopausal woman, respectively, could not be allocated to any Gardnerella species with valid names. In this work, we aimed to characterize these strains. The 16S rRNA gene sequences confirmed that these strains are members of the genus Gardnerella. Phylogenetic analysis based on cpn60 strongly supported two clades, one encompassing c17Ua_112T and nine other stra...
Source: International Journal of Systematic and Evolutionary Microbiology - November 3, 2023 Category: Microbiology Authors: M árcia Sousa Magdalena Ksiezarek Svetlana Ugarcina Perovic Tiago Antunes-Lopes Filipa Grosso Teresa Gon çalves Ribeiro Lu ísa Peixe Source Type: research
